维康药业：关于黄甲软肝颗粒启动临床三期试验的公告

Core Viewpoint - Weikang Pharmaceutical announced the initiation of a Phase III clinical trial to evaluate the efficacy and safety of Huangjia Soft Liver Granules in treating chronic hepatitis B virus-related liver fibrosis [1] Group 1: Company Information - Weikang Pharmaceutical is collaborating with Yingkerui (Zhuhai Jinwan) Pharmaceutical Co., Ltd. for the clinical trial [1] - The leading unit for the trial is Shanghai University of Traditional Chinese Medicine Affiliated Shuguang Hospital, along with 19 clinical trial centers including Anhui Medical University First Affiliated Hospital and Chongqing University Affiliated Three Gorges Hospital [1] Group 2: Clinical Trial Details - The clinical trial is designed as a randomized, double-blind, multi-center, placebo-controlled study [1] - The focus of the trial is on the effectiveness and safety of Huangjia Soft Liver Granules for patients with liver fibrosis characterized by liver qi deficiency and blood stasis [1]